The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CATX | -74.85% | -18.46% | -4% | -70% |
| S&P | +16.9% | +95.99% | +14.39% | +457% |
Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company is headquartered in Richland, WA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.29M | -44.9% |
| Gross Profit | -$0.44M | -863.0% |
| Gross Margin | -152.76% | -144.0% |
| Market Cap | $255.35M | -62.0% |
| Market Cap / Employee | $1.82M | 0.0% |
| Employees | 140 | 0.0% |
| Net Income | -$22.00M | -95.1% |
| EBITDA | -$23.31M | -70.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $28.85M | -88.6% |
| Accounts Receivable | $0.23M | 58.5% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.67M | -14.0% |
| Short Term Debt | $0.90M | 16.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -27.39% | 0.0% |
| Return On Invested Capital | -37.46% | 10.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$20.98M | -111.5% |
| Operating Free Cash Flow | -$19.95M | -124.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.64 | 0.66 | 0.52 | 0.89 | -65.23% |
| Price to Sales | 155.05 | 104.77 | 206.78 | - | |
| Price to Tangible Book Value | 3.37 | 0.85 | 0.63 | 1.09 | -87.84% |
| Enterprise Value to EBITDA | -37.81 | -0.13 | 2.55 | -2.89 | -89.46% |
| Return on Equity | -32.9% | -31.5% | - | ||
| Total Debt | $4.27M | $4.06M | $3.82M | $3.57M | -7.90% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
